San Diego-based ResMed ( RMD) reported fourth-quarter earnings that beat analysts' estimates by 1 cent. Revenue was also up 20% from last year on strong-demand for its anti-snoring devices.

ResMed's earnings were $9.8 million, or 29 cents a share, compared with First Call/Thomson Financial's estimates of 28 cents. The $9.8 million net income was up from last year's earnings of $8.3 million, or 25 cents a share. ResMed develops devices to diagnosis and treat sleep-disordered breathing.

Revenue rose to $56.2 million from $47 million a year ago.

The EPS increase was due to stronger markets for the company's sleep-disordered breathing products. ResMed said domestic sales rose 27% to $28.4 million in the quarter while foreign sales rose 13% year-over-year.

Analysts surveyed by First Call are predicting ResMed's earnings to be 28 cents a share in the first quarter of 2002.